



Tjänsteställe, handläggare  
Grants Office, Helena Nilsson

Datum  
2020-04-29

Beteckning  
Utllysningar inom  
forskning och  
innovation

## Extrainsatt nyhetsbrev från Grants Office

– stöd för extern finansiering av forskning

# Utllysningar inom medicin och hälsa för forskning och innovation relaterat till covid-19

Vecka 18

## Innehåll

Vetenskapsrådet: Flera stora satsningar på virusforskning på gång .....	4
Vetenskapsrådet: Använd en del av ditt bidrag till forskning om COVID-19 .....	4
Medel för klinisk forskning om covid-19 .....	4
Anslag till FoU-projekt om Covid-19 och arbetsmiljö .....	4
Anslag till covid-19 forskning .....	5
EU-programmet Norra Mellansverige — stödinsatser till företag mot covid-19 .....	5
Akututlysning 2020; FORMAS .....	6
KOMMER SNART: Omställningsmöjligheter och samhällseffekter av covid-19; FORMAS .....	6
Omställning av samhälle, verksamheter och produktion i spåren av coronaepidemin7 Athenapriset .....	7
Fast track process for COVID-19 co-creation request call.....	8
Biomedical Advanced Research and Development Authority broad agency announcement.....	8
COVID-19 rapid call for access to the octopus facility .....	9
Notice of special interest – clinical and translational science award programme applications to address 2019 novel coronavirus public health need .....	10
Research to support COVID-19 response in humanitarian settings .....	10
Exceptional flash call on mitigating risk in the wake of the Covid-19 pandemic.....	11
Ad hoc COVID-19 analytics and naval medical strategic planning process development .....	11
Research grants on women, victimisation and COVID-19.....	12
COVID-19 rapid collaboration call .....	12
Pipeline accelerator COVID-19 rapid response .....	13
COVID-19 competitive grant programme.....	13
EIT Health – proposals addressing the management and response to pandemics.14	
Open call for innovation – emerging innovations .....	14
Peer reviewed medical research programme – technology and therapeutic development award for emerging viral diseases and respiratory health .....	15
Peer reviewed medical research programme – investigator-initiated research award for emerging viral diseases and respiratory health .....	16
Notice of special interest – administrative supplements for research on coronavirus disease 2019 .....	16
Rapid-response grants on COVID-19 and the social sciences .....	17
COVID-19 research grant in emergency medicine .....	17

Open call for experiments – COVID 19.....	18
Anti-COVID-19 infection protective film .....	18
Notice of special interest – data driven research on coronavirus disease 2019 .....	18
Notice of special interest – emergency competitive revisions for research on severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 .....	19
Ethics and regulatory capacities .....	19
Call for access; vaccine research .....	20
Innovative approaches to enhance poverty-related diseases research .....	20
Call for solution ideas to COVID-19 challenges.....	21
Notice of special interest – emergency competitive revisions on coronavirus disease 2019 for currently active NHLBI phase I-III clinical trials.....	21
Notice of special interest – emergency competitive revisions and administrative supplements to clinical and translational science award programme awards to address 2019 novel coronavirus disease (COVID-19) public health needs .....	22
Notice of special interest – urgent competitive revisions for research on coronavirus disease 2019 (COVID-19) and the causative virus SARS-CoV-2.....	23
Notice of special interest – availability of emergency competitive revisions for research on severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 .....	23

## [Vetenskapsrådet: Flera stora satsningar på virusforskning på gång](#)

Vetenskapsrådet får 100 miljoner kronor extra i vårbudgeten för att stödja forskning om covid-19. Utöver regeringens satsning, kommer Vetenskapsrådet att stärka den grundläggande virusforskningen med 100 miljoner kronor under åren 2020–2024. [Läs mer här](#).

## [Vetenskapsrådet: Använd en del av ditt bidrag till forskning om COVID-19](#)

Du som har bidrag från Vetenskapsrådet har nu möjlighet att under en kortare tidsperiod använda delar av dina medel till forskning som relaterar till sars-CoV-2 och covid-19. [Läs mer om villkoren och hur du anmäler ändrad användning av forskningsmedel här](#).

# Utlysningar; svenska finansiärer

## [Medel för klinisk forskning om covid-19](#)

### **Svenska Läkaresällskapet, SE**

**Closing date: 30 Apr 20**

Svenska Läkaresällskapet inbjuder ansökningar om medel för klinisk forskning om covid-19. Dessa stöder klinisk forskning om covid-19, inklusive kliniska iakttagelser, patientfall och uppföljning.

Medel kan användas för egen tid, databashantering och laboratorieanalyser.

Behöriga att söka är disputerade läkare. Medlemmar i sällskapet prioriteras.

Tio anslag finns tillgängliga, värda SEK 100,000 var.

[Link to \\*Research Professional](#)

Posted date: 17 Apr 20

## [Anslag till FoU-projekt om Covid-19 och arbetsmiljö](#)

### **AFA Försäkring, SE**

**Closing date: 01 Oct 20**

Beslut kommer fattas löpande under ansökningstiden.

AFA Försäkring inbjuder ansökningar om anslag till FoU-projekt om Covid-19 och arbetsmiljö. Dessa stöder forskning- och utvecklingsprojekt om smittspridningen av Covid-19 och hur detta påverkar arbetslivet, arbetsmiljö och hälsa, arbetsmiljöarbete samt förutsättningar för ledarskap. Syftet är att främja forskning som ser till konsekvenserna för arbetslivet ur flera perspektiv för framtida kriser samt i vardagsarbetet.

Projekt ges stöd i upp till tre år.

[Link to \\*Research Professional](#)

## [Anslag till covid-19 forskning](#)

### **Hjärt-Lungfonden, SE**

**Closing date: 07 May 20**

Hjärt-Lungfonden inbjuder ansökningar om anslag till covid-19 forskning. Dessa stöder projekt inom covid-19 som har anknytning till hjärt-, kärl- eller lungsjukdom.

Forskare kan söka.

Anslag uppgår till högst SEK 500,000.

[Link to \\*Research Professional](#)

## [EU-programmet Norra Mellansverige — stödinsatser till företag mot covid-19](#)

### **Tillväxtverket, SE**

**Closing date: 07 May 20**

Tillväxtverket inbjuder ansökningar om stödinsatser till företag mot covid-19 ur EU-programmet Norra Mellansverige. Dessa stöder projekt som syftar till att öka konkurrenskraften för små och medelstora företag inom utsatta sektorer i Norra Mellansverige som har drabbats av effekterna av covid-19-krisen. Insatserna ska inkludera miljömässiga, ekonomiska och sociala hållbarhetsdimensioner i affärsutvecklingen. Perspektiv på inomregionala skillnader med hänsyn till särskilt utsatta företagare, däribland företagare med utländsk bakgrund, uppmuntras. Stöd tilldelas följande insatser:

- rådgivning och andra stödinsatser för hantering av covid-19-krisens effekter;
- rådgivning och utvecklingsprocesser för att skapa förutsättningar för att öka omställningsförmågan hos företagen;
- proaktiv hantering av uppkomna situationer med företagsnedläggning;
- rådgivning och kunskapsöverföring avseende krishantering inom företag;
- öka efterfrågan på produkter från drabbade företag eller efterfrågan som skapar nya arbetstillfällen som ersätter förlorade jobb.

Behöriga att söka är juridiska personer med hög ekonomisk och organisatorisk kapacitet samt god regional förankring. Enskilda näringsidkare och privatpersoner kan inte ansöka om stöd. Sökande med bred kompetens inom företagsrådgivning och finansiering välkomnas särskilt.

Medel täcker upp till 50 procent av stödberättigande kostnader.

Ref: 2020.5.

[Link to \\*Research Professional](#)

## [Akututlysning 2020; FORMAS](#)

### **Forskningsrådet för miljö, areella näringar och samhällsbyggande, SE**

**Sök senast: Löpande ansökningar till och med 2020-08-31.**

**Vad kan du söka för?** Akut behov av att säkerställa framtida tillgänglighet av data eller annat forskningsmaterial vid en oförutsedd händelse som inte kommer att upprepas.

Alla forskare med doktorsexamen kan söka.

Med anledning av Covid-19 och den rådande utvecklingen i Sverige och världen har Formas forskarråd beslutat att omgående öppna akututlysningen 2020. Formas vill inom rådets ansvarsområden, ge möjligheten att samla in data/forskningsmaterial av akut karaktär för att säkerställa framtida tillgänglighet för forskning.

Formas finansierar forskning inom miljö, areella näringar och samhällsbyggande. I akututlysningen välkomnar vi ansökningar inom Formas alla ansvarsområden när det föreligger ett akut behov av att säkerställa framtida tillgänglighet av data (t ex mätdata, insamling av prover) eller annat forskningsmaterial (t ex genom intervjuer, deltagande observationer). Det akuta behovet att säkerställa tillgänglighet av data/forskningsmaterial ska grunda sig på ett fenomen eller en oförutsägbar eller hastigt uppkommen situation som inte kunnat förutses och som inte kommer att upprepas.

Vi välkomnar ansökningar från samtliga vetenskapliga discipliner; humaniora, naturvetenskap, samhällsvetenskap och teknik samt inkluderar även de tvärvetenskapliga ansatserna.

Medel söks för högst ett år.

## [KOMMER SNART: Omställningsmöjligheter och samhällseffekter av covid-19; FORMAS](#)

### **Forskningsrådet för miljö, areella näringar och samhällsbyggande, SE**

**Closing date: Not open yet.**

Denna utlysning öppnas inom kort. Utlysningen beräknas öppna i mitten av maj och stänga i slutet av sommaren 2020. Nedanstående information kan komma att ändras.

Formas och Myndigheten för samhällsnydd och beredskap inbjuder ansökningar om medel för omställningsmöjligheter och samhällseffekter av covid-19. Dessa stöder projekt som utforskar vad samhället kan lära sig av coronakrisen och vilka omställningsmöjligheter och samhällseffekter som krisen kan medföra på kort och lång sikt. Medel kan sökas för projekt som bygger vidare på tidigare forskning, förberedande projekt, samt mindre och kortare forskningsprojekt.

Projekt kan pågå under upp till ett år.

[Link to \\*Research Professional](#)

## Omställning av samhälle, verksamheter och produktion i spåren av coronaepidemin

### Vinnova, SE

**Closing dates: 29 maj, 26 juni, 21 augusti och 18 september.**

Vinnova öppnar en utlysning i fyra ansökningsperioder för omställning i spåren av coronakrisen. Syftet är att möta utmaningar och fånga möjligheter som samhället nu står inför. Med det här erbjudandet ger vi stöd till initiativ som genom samverkan mobiliserar för innovation för en hållbar framtid.

**Vad kan ni söka för?** Projekt som bidrar till omställning av produktion eller verksamhet, där en första lösning är redo inom 6-12 månader. Ansökningar ska utgå från de nya behoven som uppstår på grund av corona.

**Vem kan söka?** Projekt om minst två aktörer, varav en ska vara utvecklande aktör och en behovsägare. Med behovsägare menar vi den aktör som har nytta av lösningen och som ska ta hand om (förvalta, använda, sprida) resultatet av projektet. Alla sökande parter måste vara juridiska personer.

**Hur mycket kan ni söka?** Det går att söka maximalt 1 miljon kronor per projekt. Krav på medfinansiering kan finnas. 10 miljoner är avsatt till varje bedömningsomgång.

## Athenapriset

### Vinnova, SE

**Closing date: 31 May 20**

This call is repeated once a year.

Vinnova och Dagens Medicin inbjuder nomineringar till Athenapriset. Detta syftar till att lyfta fram klinisk forskning av hög vetenskaplig kvalitet där sjukvård, akademi och näringsliv samarbetar för att utveckla sjukvården. Detta år prioriteras projekt som kan lindra konsekvenserna av covid-19 i sjukvården och samhället. Projekt ska syfta till att utveckla bättre behandlings-, och diagnostikmetoder, samt metoder eller produkter för att minska risken för smittspridning och skydda patienter och personal.

Projektet måste inkludera samarbete mellan sjukvården, akademien och näringslivet. Självnomineringar är tillåtna.

Priset är värt SEK 150,000.

[Link to \\*Research Professional](#)

# Utlysningar; internationella finansiärer

## [Fast track process for COVID-19 co-creation request call](#)

### European Open Science Cloud Secretariat, EUR

#### **Closing date: None**

You can apply for this opportunity at any time. Applications will be evaluated on a weekly basis. The European Open Science Cloud Secretariat invites applications for its fast track process for COVID-19 co-creation request call. This supports projects for product-service development that deploy open science methods and resources and make use of the EOSC communities in order to address COVID-19 related issues. The following types of activities may receive funding:

- opening up virus related research and data;
- sharing of infrastructures and services;
- developing open design equipment for fighting COVID-19;
- sharing sampling test methodologies and data;
- developing open methodologies, services, software and infrastructures for sharing data, practices and knowledge in relation to the development and treatment of COVID-19;
- developing open science methodologies for monitoring the spread of COVID-19;
- developing open-science and methodologies for the development of epidemic combating policies;
- accessing and combining open data not only to eradicate the virus but learn how to deal with similar viruses and future outbreaks;
- assessing the validity of epidemic information in relation to the virus by ensuring that its sources can be traced and verified;
- other open science activities and actions related to the fighting of epidemics and pandemics.

Individuals or natural persons and legal entities residing in EU member states, including their outermost regions and associated countries may apply. Applicants may not be receiving support from other instruments for the proposed activities.

Grants are worth up to €45,000 each.

Country of applicant institution: EU (European Union); EU Associated Countries

[Link to \\*Research Professional](#)

## [Biomedical Advanced Research and Development Authority broad agency announcement](#)

### US Department of Health and Human Services, US

#### **Closing date: 30 Apr 20**

Applications due by 4.30pm ET on selected due dates. Deadlines on: 30 April 2020, 31 July 2020, 31 October 2020.

The US Department of Health and Human Services invites proposals for its Biomedical Advanced Research and Development Authority (BARDA) broad agency announcement. This supports advanced research and development of medical countermeasures for chemical, biological, radiological and



nuclear (CBRN) agents, pandemic influenza, and emerging infectious diseases that threaten the US civilian population, with a particular focus on COVID-19. Projects must address at least one of the following areas of interest:

- CBRN vaccines;
- CBRN antitoxins and therapeutic proteins;
- antibacterials;
- radiological and nuclear threat medical countermeasures;
- chemical threat medical countermeasures;
- burn medical countermeasures;
- diagnostics;
- influenza and emerging infectious diseases vaccines;
- influenza and emerging infectious diseases therapeutics;
- respiratory protective devices;
- ventilators;
- advanced manufacturing technologies.

Applications must be for research that directly relates to COVID-19.

Country of applicant institution: Any

[Link to \\*Research Professional](#)

## [COVID-19 rapid call for access to the octopus facility](#)

### **Science and Technology Facilities Council, GB**

#### **Closing date: 01 May 20**

Applications are accepted on a rolling basis until 1 May 2020, with the possibility of extension depending on circumstances at the time. Successful proposals will be scheduled on a first come, first served basis.

The Science and Technology Facilities Council's Central Laser Facility invites applications for its COVID-19 rapid call for access to the octopus facility. This enables researchers to use the Octopus imaging facility for research relevant to the SARS-CoV-2 virus and COVID-19. The facility offers a comprehensive range of optical microscopy instruments and techniques including super-resolution, single molecule imaging and tracking, light sheet microscopy, Förster resonance energy transfer by fluorescence lifetime imaging (FRET-FLIM) and optical trapping and tweezers. It also offers a Zeiss crossbeam cryo focused ion beam-scanning electron microscope with slice and view capability. To maintain social distancing, physical microscopy will be undertaken by expert staff with samples being sent to the facility. Communication with users before and during the experiments will be made by video link or telephone and remote access to the microscopy instruments will be available. Live virus work is not eligible and samples sent to the site must be tested and certified as non-infective in advance. Researchers in academia or industry worldwide may apply. There are no charges for access to the facility for successful applicants.

[Link to \\*Research Professional](#)

## **Notice of special interest – clinical and translational science award programme applications to address 2019 novel coronavirus public health need**

### **NIH: National Center for Advancing Translational Sciences, US**

**Closing date: 04 May 20**

Applications due by 5pm local time of applicant organisation. Deadlines on: 4 May 2020, 2 November 2020.

The National Center for Advancing Translational Sciences invites applications for its notice of special interest – clinical and translational science award (CTSA) programme applications to address 2019 novel coronavirus public health need funding opportunity. This supports research on the 2019 novel coronavirus (COVID-19), with a particular focus on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to advance the translation of research findings into diagnostics, therapeutics and vaccines.

Applicants must hold an active parent award and submit their funding request using the PA-18-591 funding opportunity or its reissue.

The project duration is limited to the remaining active budget period that started in the current fiscal year for the existing parent award.

Ref: NOT-TR-20-011.

[Link to \\*Research Professional](#)

## **Research to support COVID-19 response in humanitarian settings**

### **Enhancing Learning and Research for Humanitarian Assistance, GB**

**Closing date: 04 May 20**

Applications due by 6pm GMT+1.

Enhancing Learning and Research for Humanitarian Assistance invites applications for its call for research to support COVID-19 response in humanitarian settings. This aims to support research focusing on priority topics related to the current COVID-19 outbreak in humanitarian settings in low- and middle -income countries. Research must target either refugees, internally displaced people and other conflict-affected people in camps or urban humanitarian settings, or health systems and health care workers supporting the COVID-19 response in these settings in LMIC.

Applicants can be based in any country in the world, and must apply as part of an established organisation. The research team should include academic and humanitarian partners, as appropriate.

[Link to \\*Research Professional](#)

## [Exceptional flash call on mitigating risk in the wake of the Covid-19 pandemic](#)

### **AXA Research Fund, FR**

#### **Closing date: 07 May 20**

Proposals due by 4pm Paris time.

The AXA Research Fund invites proposals for its exceptional flash call on mitigating risk in the wake of the Covid-19 pandemic. This supports research related to the mitigation of risk after the Covid-19 pandemic or a potential second wave, particularly in lower income countries. Projects may address one of the following topics:

- protecting vulnerable populations from epidemics and catastrophes, including Covid-19;
- improving data collection and quality in health;
- understanding the effects of confinement and social distancing;
- early warning and preparedness;
- preserving the environment and health.

Mid-career researchers who received their PhD between six and ten years ago and are currently based at an academic institution, may apply. Exceptions to the time frame are made only for maternity leave. Ideally, applications should go through an institution, who may suggest one candidate per department. Projects may include NGOs, governmental bodies, foundations, cultural institutions and hospitals as collaborators.

Grants are worth up to €250,000 over between 12 and 24 months. Grants cover salary of the researcher, PhD students, postdoctoral researchers and research assistants, as well as equipment, conferences, workshops, field work and outreach activities.

[Link to \\*Research Professional](#)

## [Ad hoc COVID-19 analytics and naval medical strategic planning process development](#)

### **US Department of Defense, US**

#### **Closing date: 07 May 20**

This is a one-off opportunity. We do not expect future rounds. Applications due by 5pm EDT.

The US Department of Defense invites applications for its ad hoc COVID-19 analytics and naval medical strategic planning process development funding opportunity. This supports adding analytic capacity to specifically pertaining to COVID-19 response planning and making forward progress in the establishment of a naval medical strategic planning process.

Country of applicant institution: Any

The anticipated period of performance is four and half months.

Ref: N6311620ADV0001.

[Link to \\*Research Professional](#)

## [Research grants on women, victimisation and COVID-19](#)

### **National Bureau of Economic Research, US**

#### **Closing date: 11 May 20**

This is a one-off opportunity. We do not expect future rounds. Applications due by 11.59pm EDT.

The National Bureau of Economic Research, with sponsorship from the Bill and Melinda Gates Foundation, invites applications for its research grants on women, victimisation and COVID-19. This supports research on women, victimisation and domestic violence, with a particular emphasis on the impact of the current COVID-19 pandemic. Projects may focus on developing or developed countries. Applicants must be based at an academic institution. Applications are especially welcome from untenured faculty members, postdoctoral and advanced doctoral students and researchers who are members of groups that are underrepresented in economics.

Country of applicant institution: Any

Up to four grants, worth USD 20,000 each, are available.

[Link to \\*Research Professional](#)

## [COVID-19 rapid collaboration call](#)

### **European Health Data and Evidence Network, BE**

#### **Closing date: 14 May 20**

Applications due by 5pm CET.

The European Health Data and Evidence Network invites applications for its COVID-19 rapid collaboration call. This aims to enable quicker open science by supporting institutions in harmonising COVID-19 clinical data to the observational medical outcomes partnership common data model. The following data source types of longitudinal, person-level observational health data may be submitted:

- electronic health records;
- claims data;
- hospital data;
- registry data;
- COVID-19 cohort data.

Any institution established in an EU member state or Horizon 2020 associated country may apply.

The total budget is €1 million and grants are worth up to €50,000. Successful applicants will also receive assistance from technical experts to assist with remote harmonisation of data, and will be invited to participate in further COVID-19 research studies.

[Link to \\*Research Professional](#)

## [Pipeline accelerator COVID-19 rapid response](#)

### **Therapeutic Innovation Australia, AU**

**Closing date: 15 May 20**

Therapeutic Innovation Australia invites applications for its pipeline accelerator COVID-19 rapid response call. This aims to provide rapid support to Australian researchers engaged in research related to COVID-19 through access to a network of core- and screening facilities. This call focus solely on projects related to COVID-19, including any aspect of the national or global response, such as high throughput screening, assay development, drug repurposing, diagnostic development, pre-clinical and clinical trial support, analytical validation, pilot scale production.

Applications are open to university-based researchers and research groups, research groups within public funded research organisations, including medical research institutes, university or medical research institute's technology transfer office, or organisations and commercial entities that meet the general eligibility criteria for the R&D tax incentive. Applications from international organisations will also be considered. The project must require access to a TIA -supported facilities and applications must be made with this centre's involvement and agreement. Multiple providers can be named on an application if the project makes use of capabilities at several different facilities.

Two levels of funding are offered; multiple grants of AUD 5,000 each, up to a total value of AUD 20,000 or a single grant of AUD 50,000 provided directly to the service provider. Applications are expected to demonstrate a cash co-investment of at least 25 per cent of the requested award.

[Link to \\*Research Professional](#)

## [COVID-19 competitive grant programme](#)

### **Pfizer, INT**

**Closing date: 22 May 20**

This is a one-off opportunity. We do not expect future rounds.

Pfizer invites applications for its COVID-19 competitive grant programme. This supports research on COVID-19. The following grants are available:

- independent medical education grants – to support educational programmes for healthcare providers focused on the recognition, diagnosis, treatment and overall care management of patients with COVID-19;
- quality and process improvement grants – to support hospitals or healthcare systems so that they may evaluate and improve their systems of care for COVID-19 patients.

Clinical research projects and projects evaluating the efficacy of therapeutic or diagnostic agents are not eligible.

Medical, dental, nursing, allied health and pharmacy professional schools, large and small healthcare institutions, professional associations, government agencies, and other entities with a mission related to healthcare improvement, anywhere in the world, may apply. Only organisations are eligible, not individuals or medical practice groups.

The total budget is USD 5 million. Grants are worth between USD 20,000 and USD 250,000 each.

[Link to \\*Research Professional](#)

## [EIT Health – proposals addressing the management and response to pandemics](#)

### **European Institute of Innovation and Technology, EU**

#### **Closing date: 27 May 20**

Expressions of interest due by 4pm Munich time.

The European Institute of innovation and Technology, under EIT Health, invites proposals addressing the management and response to pandemics. These grants support research into the prevention and management of the COVID-19 pandemic as well as potential future pandemics. Projects may address one or more of the following topics:

- hindering disease spread and prevention of outbreaks – social distancing measures, travellers' tracking and monitoring and contagiousness, confinement and hygiene management;
- optimising screening and diagnosis – efficient testing on a permanent level to control future outbreaks, evaluation of digital biomarkers, remote triage, assessment of acquired immunity, triaging of infected persons to determine optimal treatment;
- treating people better – secondary infections treatment, management of other diseases, remote care of the sick and vulnerable, healthcare services at elderly homes, intelligent monitoring of patients during treatment;
- healthcare organisation's resource management, logistics and supply chains – healthcare facilities resource management, security of supply of essential medical equipment and resilience of global supply chains, shortage of medical staff;
- data-driven initiatives – utilisation of big data, services for various applications, particularly focusing on transnational approaches for accelerated information and data sharing.

Projects may apply for innovation, campus or accelerator grants. Innovation projects aim for rapid market penetration of innovative products and services. Campus projects cover training for students, entrepreneurs, innovators, healthcare professionals and executive and citizens and patients.

Accelerator projects cover bootcamp programmes and helping start-ups.

Proposals must be submitted by an EIT health core or associate partner or a linked third party.

Country of applicant institution: EU member states.

Grants cover up to 80 per cent of costs.

[Link to \\*Research Professional](#)

## [Open call for innovation – emerging innovations](#)

### **Ministry of Defence, GB**

#### **Closing date: 28 May 20**

Proposals due by 12 noon. Deadlines on: 28 May 2020, 30 July 2020, 1 October 2020, 3 December 2020, 28 January 2021, 31 March 2021.

The Ministry of Defence, under the Defence and Security Accelerator programme and in partnership with Innovate UK, invites proposals for its emerging innovations call. This encourages proposals across a wide range of technology areas with the aim of finding new and novel opportunities for these to be exploited across defence or security. Emerging innovations are viewed as those which will

deliver a proof of concept at around technology readiness level 3 or 4. Proof-of-concept may include component or subsystem validation in a laboratory-style environment. Projects are expected to start at technology readiness level 2 or 3, which means the basic concept has been formulated and the underpinning technological principles observed at the outset. Projects that deliver successfully in this category may be candidates for follow-on funding in the rapid impact innovation category, although other funding opportunities may be available. Whilst proposals may address any topic that is of relevance to the defence and security sector, the call also has the following innovation focus areas:

- COVID-19 - rapid sanitising technology;
- reduced-burden area biosurveillance;
- detecting firearms and ammunition through scent;
- next generation aviation security;
- innovative security features for bank notes – DASA terms and conditions do not apply, and direct contracts will be negotiated with the Bank of England;
- advancing less-lethal weapon capability;
- regenerative medicine at the front line;
- assistive technology for rail staff;
- screening train carriages.

Applications are open to all organisation types and individuals. There are no nationality restrictions.

Proposals are accepted from the private sector, academia and individuals in the UK or overseas.

The majority of successful projects cost between £50,000 and £100,000 and last between three and 10 months.

[Link to \\*Research Professional](#)

## [Peer reviewed medical research programme – technology and therapeutic development award for emerging viral diseases and respiratory health](#)

### **US Department of Defense, US**

#### **Closing date: 28 May 20**

Pre-applications due by 5pm, 28 May 2020; applications due by 11.59pm, 12 June 2020.

The US Department of Defense, under its peer reviewed medical research programme, invites applications for its technology and therapeutic development award for emerging viral diseases and respiratory health. This supports the translation of promising preclinical findings into products for clinical applications in emerging viral diseases and respiratory health. Products in development should be responsive to the healthcare needs of military service members veterans or beneficiaries. Projects must fall under at least one of the emerging viral diseases or respiratory health focus areas related to COVID-19 and acute respiratory distress syndrome.

Independent investigators at or above the level of assistant professor based at any organisation anywhere in the world may apply.

The total budget is USD 25 million to fund up to four awards. Grants are worth up to USD 4m each for up to four years.

[Link to \\*Research Professional](#)

## [Peer reviewed medical research programme – investigator-initiated research award for emerging viral diseases and respiratory health](#)

### **US Department of Defense, US**

#### **Closing date: 28 May 20**

Pre-applications due by 5pm ET, 28 May 2020; applications due by 11.59pm ET, 12 June 2020.

The US Department of Defense, under its peer reviewed medical research programme, invites applications for its investigator-initiated research award for emerging viral diseases and respiratory health. This supports studies that will make an important contribution toward research or patient care in the areas of emerging viral diseases and respiratory health. Research must address at least one of the emerging viral diseases or respiratory health focus areas related to COVID-19 and acute respiratory distress syndrome. Projects may focus on any phase of research from basic laboratory research through to translational research, but must have the

potential to yield highly impactful data that could lead to critical discoveries or major advancements.

Independent investigators at or above the level of assistant professor based at any organisation anywhere in the world may apply. Two investigators may submit an application under the partnering PI option and will each receive a separate award.

The total budget is USD 12 million to fund approximately four awards. Grants are worth up to USD 1.6m each for up to four years for a single PI or up to USD 2m each for up to four years for applications under the partnering PI option.

[Link to \\*Research Professional](#)

## [Notice of special interest – administrative supplements for research on coronavirus disease 2019](#)

### **NIH: National Library of Medicine, US**

#### **Closing date: 01 Jun 20**

Applications due by 5pm local time of applicant organisation.

The National Library of Medicine invites applications for its notice of special interest – administrative supplements for research on coronavirus disease 2019 funding opportunity. This supports research on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19). The aim is to improve our understanding of SARS-CoV-2 and COVID-19. Research is expected to focus on informatics and data science methods to help address the COVID-19 pandemic and should address one of the following areas of interest:

- methods for mining clinical data that can be used to identify or predict presence of COVID-19 in biomedical phenotype data;
- public health surveillance methods that mine genomic, viromic, health data, environmental data or data from other pertinent sources to identify spread and impact of SARS-Cov-2.

US and foreign non-profit and for-profit organisations may apply. Applicants must hold an active parent award and submit their funding request using the PA-18-591 funding opportunity.

Awards are worth up to USD 75,000 each for up to one year.

[Link to \\*Research Professional](#)



## [Rapid-response grants on COVID-19 and the social sciences](#)

### **Social Science Research Council, US**

**Closing date: 01 Jun 20**

This is a one-off opportunity. We do not expect future rounds. Applications due by 11.59pm EST.

The Social Science Research Council, with support from the Henry Luce Foundation, invites applications for its rapid-response grants on COVID-19 and the social sciences. These support innovative research projects that deploy remote research methods to shed light on both the short- and potential long-term effects of COVID-19 across a range of issues.

Projects focused on groups most affected by the pandemic are especially encouraged, as are those that can constructively inform responses across communities, public actors and institutions, and others.

Researchers who hold a PhD in any social science discipline or related interdisciplinary field may apply.

Country of applicant institution: Any

Grants are worth between USD 2,000 and USD 5,000 each for up to six months. Collaborative projects may receive slightly more support.

[Link to \\*Research Professional](#)

## [COVID-19 research grant in emergency medicine](#)

### **Emergency Medicine Foundation, US**

**Closing date: 05 Jun 20**

Applications due by 6pm EST. We invite applications for its COVID-19 research grant. This supports research that will provide high-impact new knowledge to advance emergency patient care, improve response of hospitals, healthcare and emergency medical services systems, and protect emergency medicine healthcare professionals during pandemics. Topics may include the following areas:

- personal protective equipment, including design, cleaning and reuse;
- ventilator scarcity;
- telemedicine;
- laboratory testing;
- rapid screening, triage and testing;
- clinical diagnosis;
- epidemiology of disease;
- therapeutics;
- diagnostic radiology, including point of care ultrasound;
- emergency medicine workforce, including safety;
- emergency physician wellness;
- special populations, such as high-risk, homeless, non-English-speaking and transplantation patients.

Applicants must be emergency physicians. Co-investigators from the emergency medicine team or other disciplines are encouraged. Country of applicant institution: Any

The total budget is USD 100,000. Grants are worth between USD 10,000 and USD 50,000 each for six months. [Link to \\*Research Professional](#)

## [Open call for experiments – COVID 19](#)

### **Smart Emerging Electronics Servicing, CZ**

**Closing date: 05 Jun 20**

The Smart Emerging Electronics Servicing (SmartEEs) invites applications for its open call for experiment – COVID-19. This supports projects that directly contribute to reducing the spread of COVID-19 and other viruses through flexible wearable electronics as solutions in, among others, the field of prevention, diagnostics and therapy.

SMEs, start-ups and mid-caps, innovative tech companies or traditional non-tech industries from all activities fields legally established in EU member states, overseas countries and territories and H2020 associated countries, may apply.

Support is worth up to €100,000 for each application, consisting of €60,000 worth of technical services, up to €20,000 worth a voucher, and up to €20,000 towards non-technical activities. In-kind contributions are required.

Ref: SmartEEs203-2020, 872076

[Link to \\*Research Professional](#)

## [Anti-COVID-19 infection protective film](#)

### **InnoCentive, GB**

**Closing date: 15 Jun 20**

This is a one-off opportunity. We do not expect future rounds. Submissions due by 11.59pm US Eastern time.

InnoCentive invites submissions for its anti-COVID-19 infection protective film challenge. This seeks ideas for a thin film that, when applied to hands and other open parts of the human body, would prevent people from being infected with COVID-19. Country of applicant institution: Any

Awards are worth USD 1,000 each.

Ref: 9934290.

[Link to \\*Research Professional](#)

## [Notice of special interest – data driven research on coronavirus disease 2019](#)

### **NIH: National Library of Medicine, US**

**Closing date: 16 Jun 20**

This is a one-off opportunity. We do not expect future rounds. Applications due by 5pm local time of applicant organisation. The National Library of Medicine invites applications for its notice of special interest – data driven research on coronavirus disease 2019 funding opportunity. This supports research to improve understanding of the infection of severe acute respiratory syndrome coronavirus (SARS-CoV-2) and coronavirus disease 2019 (COVID-19). The following areas are of interest:

- methods for mining clinical data that can be used to identify or predict presence of COVID-19 in biomedical phenotype data;

•public health surveillance methods that mines genomic, viromic, health data, environmental data or data from other sources to identify spread and impact of SARS-CoV-2.

US and foreign non-profit and for-profit organisations may apply. Applicants must hold an active parent award and submit their funding request using the PA-18-591 funding opportunity. Application budgets are limited to USD 275,000 for a two-year period, with no more than USD 200,000 in any year.

Ref: NOT-LM-20-011.

[Link to \\*Research Professional](#)

## **Notice of special interest – emergency competitive revisions for research on severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019**

### **NIH: Office of the Director, US**

#### **Closing date: 19 Jun 20**

This is a one-off opportunity. We do not expect future rounds. Applications are reviewed on a rolling basis until 5pm local time of applicant organisation, 19 June 2020.

The Office of Strategic Coordination invites applications for its notice of special interest – emergency competitive revisions for research on severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019. This supports research focusing on prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. The aim is to rapidly improve the understanding, diagnosis and treatment of COVID-19. Any relevant area of innovative research is welcome, including behavioural and social science research, research on health disparities, novel therapeutics and other related topics.

US and foreign for-profit and non-profit organisations and public and private organisations may apply. Applicants must hold an active parent award. Administrative supplement requests must be submitted using the PA-20-135 funding opportunity. Eligible activity codes are D43, DP2, DP5, DP7, R01, R24, R25, R35, U01, U18, U19, U24, U2C, U2R, U42, U54, UG3, UH2, UH3 and UM1.

The maximum project period is one year. Application budgets should not exceed the annual amount of the current parent award and should reflect the actual needs of the proposed project.

Ref: NOT-RM-20-015.

[Link to \\*Research Professional](#)

## **Ethics and regulatory capacities**

### **European and Developing Countries Clinical Trials Partnership, NL**

#### **Closing date: 16 Jul 20**

Applications due by 5pm.

The European and Developing Countries Clinical Trials Partnership invites applications for its ethics and regulatory capacities call. This supports sub-Saharan African countries in establishing and developing robust national medicines regulatory systems and capacities for ethical review of clinical

research and use of medicinal products and technologies for use in humans. Within this, applicants should also consider the global COVID-19 crisis.

Applications must include at least one legal entity established in a European participating state or a sub-Saharan African country. Additionally, applications must include at least one legal entity hosting national ethics committee and national regulatory authorities in sub-Saharan countries.

The total budget is € 2.5 million. Six to eight grants are available, each worth up to €500,000 for two years.

Ref: CSA2020ERC.

[Link to \\*Research Professional](#)

## [Call for access; vaccine research](#)

### **European Network of Vaccine Research and Development, EU**

**Closing date: 05 Aug 20**

Applications may be submitted at any time and will be processed at pre-defined cut-off dates.

Deadlines on: 15 December 2019, 15 April 2020, 5 August 2020, 15 December 2020.

The European Network of Vaccine Research and Development invites applications for its call for access. This supports and accelerates vaccine-related projects in the preclinical phase of development, by providing access to the services and expertise contained within the Transvac infrastructure.

COVID-19 vaccine development projects are encouraged to apply.

The user group leader and majority of the users in the group must work in an institution established in an EU member state or an associated state. They must work in a different country than the Transvac partner whose service they wish to access.

In addition to free access to services, Transvac may cover accommodation and travel costs if a physical visit to the infrastructure is needed.

[Link to \\*Research Professional](#)

## [Innovative approaches to enhance poverty-related diseases research](#)

### **European and Developing Countries Clinical Trials Partnership, NL**

**Closing date: 13 Aug 20**

Applications due by 5pm.

The European and Developing Countries Clinical Trials Partnership invites applications for its call on innovative approaches to enhance poverty-related diseases research. This supports small- to medium-scale clinical trials or clinical research studies that deliver proof-of-concept or validation of smart, highly innovative technologies or concepts to prevent, treat or diagnose PRDs in sub-Saharan Africa. Proposals may address any disease or group of diseases within the scope of EDCTP. Proposals should include one small- to medium-scale studies in sub-Saharan Africa. Proposals that combine medical and pharmaceutical technologies with other scientific areas such as mobile technologies and digital technologies, big data processing, and other emerging technologies are particularly encouraged, as are

proposals involving small- or medium-sized enterprises. Within this, proposals should also consider the global COVID-19 crisis.

Applications must consist of at least three legal entities, two of which must be established in to different participating EU partner states and one in a Sub-Saharan country.

The total budget is €23.4 million. Between five and 15 grants are available. Projects must start by 1 October 2021 and be completed by the end of 2024.

Ref: RIA2020I.

[Link to \\*Research Professional](#)

## **Call for solution ideas to COVID-19 challenges**

### **AMable, DE**

#### **Closing date: 01 Oct 20**

AdditiveManufacturABLE (AMable) invites applications for its call for solution ideas to COVID-19 challenges. This supports additive manufacturing projects that may contribute to solving practical challenges in managing the COVID-19 pandemic.

Natural persons or legally recognised companies registered within the EU or a Horizon 2020 linked country. Preference is given to SMEs and midcaps. Research and technology development organisations are not eligible, nor consortium members.

The total budget is worth €350,000 and grants are worth up to €10,000 for experiments lasting between six and 12 weeks. Grants may cover up to 70 per cent of direct costs.

[Link to \\*Research Professional](#)

## **Notice of special interest – emergency competitive revisions on coronavirus disease 2019 for currently active NHLBI phase I-III clinical trials**

### **NIH: National Heart, Lung and Blood Institute, US**

#### **Closing date: 05 Oct 20**

This is a one-off opportunity. We do not expect future rounds. Applications are reviewed on a rolling basis between 1 May 2020 and 5pm local time of applicant organisation, 5 October 2020.

The National Heart, Lung and Blood Institute invites applications for its notice of special interest – emergency competitive revisions on coronavirus disease 2019 for currently active NHLBI I-III clinical trial funding opportunity. This supports research focusing on the safety and efficacy of interventions for primary prevention or treatment of COVID-19, associated clinical phenotypes and surrogate outcomes relevant to heart, lung and blood diseases. The aim is to rapidly initiate and conduct phase I and phase I and II bridging clinical trials in patients at risk for severe acute respiratory syndrome coronavirus 2 infection or patients with COVID-19.

US and foreign non-profit and for-profit organisations may apply. Applications for this initiative must be submitted to PA-20-135 emergency competitive revision to existing NIH awards (emergency supplement – clinical trial optional) or its subsequent reissued equivalent. Applicants must be part of

programmes that are actively conducting phase I to III clinical trials. It is encouraged that the activity code of the parent award is P01, R01, R33, R41, R42, R43, R44, U01, U24, U54, UH3 or UM1. Applicants are expected to ensure qualified personnel and site capabilities for the safe conduct of phase I and phase I and II bridging for COVID-19.

The maximum project period is two years.

Ref: NOT-HL-20-782.

[Link to \\*Research Professional](#)

## [Notice of special interest – emergency competitive revisions and administrative supplements to clinical and translational science award programme awards to address 2019 novel coronavirus disease \(COVID-19\) public health needs](#)

### **NIH: National Center for Advancing Translational Sciences, US**

#### **Closing date: 10 Nov 20**

This is a one-off opportunity. We do not expect future rounds. Applications are invited between 4 May and 5pm local time of the applicant organisation, 10 November 2020.

The National Center for Advancing Translational Sciences invites applications for its emergency competitive revisions and administrative supplements to clinical and translational science award programme awards to address 2019 novel coronavirus disease (COVID-19) public health needs funding opportunity. This supports projects in translational science that address the COVID-19 public health emergency. Funding will be awarded to current clinical and translational science UL1 and U24 award holders for the following responsive activities:

- RFA-TR-17-006 data to health coordinating centres (U24) – digital health platforms and models that integrate data, assess risk and provide illness or infection surveillance, management tools and inform clinical practice. Up to one award is available;
- RFA-TR-15-002 trial innovation centres (U24) and RFA-TR-15-004 network recruitment innovation centres (U24) – planning of COVID-19 trials, additional recruitment and retention support, eConsent support, and provision of a platform and statistical expertise to collect and perform meta-analyses of COVID-19 therapeutic trials. Up to four awards are available;
- PAR-18-940, PAR-18-464, PAR-15-304 and RFA-TR-14-009 clinical and translational science awards (U54 clinical trial optional) UL1 component only – provision of clinical data in specified formats to support illness, infection status, surveillance determinations or clinical study data. Between five and 15 awards are available worth between USD 50,000 and USD 100,000;
- PAR-18-940, PAR-18-464, PAR-15-304 and RFA-TR-14-009 clinical and translational science awards (U54 clinical trial optional) UL1 component only – involvement with clinical studies and trials in support of COVID interventions, as well clinical sample provision and assessing infectious or convalescent status. Up to ten awards are available.

US and foreign for-profit and non-profit organisations and public and private organisations may apply. PIs must hold an active grant or cooperative agreement. Administrative supplement requests must be submitted using PA-20-135 or PA-18-591 funding opportunities.

The project period is generally limited to one year. Project periods up to two years will be considered only with strong justification. Application budgets may exceed the amount of the current parent award with strong justification and must reflect the actual needs of the proposed project.

Ref: NOT-TR-29-028.

[Link to \\*Research Professional](#)

## **Notice of special interest – urgent competitive revisions for research on coronavirus disease 2019 (COVID-19) and the causative virus SARS-CoV-2**

### **NIH: National Institute of General Medical Sciences, US**

**Closing date: 05 Feb 21**

This is a one-off opportunity. We do not expect future rounds. Applications are reviewed on a rolling basis until 5pm local time of applicant organisation, 5 February 2021.

The National Institute of General Medical Sciences invites applications for its urgent competitive revisions for research on coronavirus disease 2019 (COVID-19) and the causative virus (SARS-CoV-2) funding opportunity. This supports research aimed at better understanding SARS-CoV-2, improving the predictive quality of existing models of spread, diagnostics for measurement of transmission, susceptibility and recovery and development of therapeutic interventions. Projects must focus on one of the following areas of interest:

- incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents;
- repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection;
- rapid development of potential therapeutic agents for COVID-19.

US and foreign for-profit and non-profit organisations and public and private organisations may apply. PIs must hold an active grant or cooperative agreement. Administrative supplement requests must be submitted using the PA-18-935 funding opportunity.

Application budgets are limited to no more than the amount of the current parent award and must reflect the actual needs of the proposed project. The maximum project period is one year.

Ref: NOT-GM-20-025.

[Link to \\*Research Professional](#)

## **Notice of special interest – availability of emergency competitive revisions for research on severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019**

### **NIH: National Institute of Allergy and Infectious Diseases, US**

**Closing date: 25 Mar 21**

This is a one-off opportunity. We do not expect future rounds. Applications accepted on a rolling basis until 5pm local time of applicant organisation, 25 March 2021.

The National Institute of Allergy and Infectious Diseases and the National Institute on Alcohol Abuse and Alcoholism invite applications for their notice of special interest – availability of emergency competitive revisions for research on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) funding opportunity. This supports research on SARS-CoV-2 and COVID-19 with a particular focus on viral natural history, pathogenicity and transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics. Projects should address one of the following areas of interest:

- studies to identify optimal in vitro culture requirements and conditions;
- development of reagents and assays for virus characterisation;
- studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;
- studies to identify viral epitopes critical for binding neutralisation;
- studies to examine virus stability and persistence;
- production of molecular clones of SARS-CoV-2, reporter viruses and recombinant viral proteins;
- development of animal models of SARS-CoV-2 infection suitable for screening vaccine and therapeutic candidates or pathogenesis studies;
- studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence;
- virologic and serologic surveillance studies of the distribution and natural history of SARS-CoV-2 viruses in animal populations and in humans with particular emphasis on host reservoirs and understanding cross-species transmission events;
- development of sensitive, specific and rapid clinical diagnostic tests for SARS-CoV-2;
- development of SARS-CoV-2 therapeutic candidates;
- identification and evaluation of the innate, cellular and humoral immune responses to SARS-CoV-2 infection and candidate vaccines;
- development of SARS-CoV-2 vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralisation potential of SARS-CoV vaccine candidates.

US and foreign non-profit and for-profit organisations may apply. Applicants must hold an active NIH award. Applicants must hold an active parent award and submit their funding request using the PA-20-135 funding opportunity.

Application budgets should not exceed the annual amount of the current parent award and should reflect the actual needs of the proposed project. The maximum project duration is two years.

Ref: NOT-AI-20-034.

[Link to \\*Research Professional](#)